Articles tagged with 'PRESSEMELDUNG' | Bayer

Despite available treatment options, many patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are progressing to kidney failure and premature death / Kerendia™ (finerenone) is the first non-steroidal, selective mineralocorticoid rece...

Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need / Strategic investment of $140M USD to expand presence in leading center of biotech innovat...

AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity / Cloud-hosted platform provides access to AI applications that integrate into standard medical imaging workflow / Market introduction t...

SAN DIEGO - June 23, 2022 - Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorde...

Berlin, June 21, 2022 - The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with ...

Innovative business model preserves Vividion’s entrepreneurial culture and pipeline focus, while adding the technical expertise and resources of a global pharma leader / Multiple programs for previously undruggable targets now advancing towards the c...

Establishment of BlueRock site in Berlin expands company’s footprint and strengthens Bayer’s cell therapy capabilities / Acceleration of the development of cell therapies in BlueRock’s pipeline, with initial focus on the ongoing BRT-DA01 clinical tri...

New post-hoc analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, evaluated the effect of Kerendia™ (finerenone) by baseline HbA1c categories, HbA1c variability, and diabetes duration in patients with chronic kidney d...

Initiation of global non-interventional study for patients with Parkinson’s planned for the second half of 2022 as next step...

Pledge commitment to achieve Zero Hunger by 2030 for regions within Asia, Africa and Latin America / Pledge includes large commitment of vegetable and rice seeds which form part of the company's broader sustainability commitments / Bayer will work to...

Data from the exploratory post hoc analysis of FIDELITY also highlight the potential of Kerendia™ (finerenone) to reduce the incidence of hospitalization for heart failure (HHF), with a more pronounced effect in patients with left ventricular hypertr...

Results from the extension part of the COMPASS study support the long-term use of Xarelto (rivaroxaban) plus aspirin for vascular protection in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) / The XATOA reg...

Prostate cancer remains a key focus area with darolutamide data in non-metastatic castration-resistant prostate cancer (high-risk nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 dichloride research in metastatic castr...

Studied in adults with symptomatic chronic heart failure and reduced ejection fraction who are stabilized after a recent decompensation event with IV therapy / Approved in China to reduce the risk of heart failure (HF) hospitalization or the need for...

New subgroup analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will reveal further insights into the efficacy and safety of Kerendia™ (finerenone) in patients with stage 4 chronic kidney disease (CKD) and type 2 di...

Investment of approximately 275 million euros in the world’s first learning pharmaceutical production facility / 70 percent lower CO2 emissions than conventional plants...

Group sales grow by 14.3 percent (Fx & portfolio adj.) to 14.639 billion euros / EBITDA before special items increases by 27.5 percent to 5.251 billion euros / Substantial sales and earnings growth at Crop Science and Consumer Health / Sales up sligh...

Application is being reviewed concurrently among participating international health authorities under the FDA Oncology Center of Excellence’s (OCE) Project Orbis initiative...

...

Chairman of the Board of Management...

Chairman of the Supervisory Board of Bayer AG...

Operationally and strategically successful in 2021 / Dividend of 2.00 euros per share proposed / Very successful start to 2022...

Projected transaction supports efforts to accelerate expansion of a diversified portfolio of high-quality microbial-based solutions for growers around the world by further enhancing Bayer’s biologics strategy of tapping into the open innovation ecosy...

Submission to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for an additional indication in patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Submission based on data from the pivota...

Berlin, April 21, 2022 - Bayer today announced Tara Frenkl, MD, MPH as the new Head of Oncology Development at its Oncology Strategic Business Unit, effective April 25, 2022. She will report to Christine Roth, Head of the Oncology Strategic Business ...

Precision oncology treatment Vitrakvi™ (larotrectinib) approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors in adult and pediatric patients in China / In clinical studies of patients with TRK fusion solid tumors, laro...

Focus on innovative and sustainable solutions in Fruits and Vegetables (Hall 1.2, Stand B-06) / Progress updates on Food Chain Partnerships that connect growers to the food value chain / Introduction of new BIOLOGICALS by Bayer® signet...

Cardiovascular (CV) complications are among the most frequent causes of death for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), with atherosclerotic CV disease (ASCVD) on top of CKD and T2D having the highest risk of all-cause...

In the prospective observational XARENO study, after one year follow up, Xarelto was associated with a greater net clinical benefit and a reduced risk of kidney failure in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kid...

Thrive for Change winning projects include work to eliminate food waste in Bolivia, put vegetable production tools into the hands of African farmers and use microalgae to eliminate nutrient pollution in the world’s water / Winners are delegates from ...